Reported Monday, Daiichi Sankyo And AstraZeneca's Datopotamab Deruxtecan Show Survival Improvement Versus Chemotherapy In Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer In TROPION-Lung01 Phase 3 Trial
Portfolio Pulse from Benzinga Newsdesk
Daiichi Sankyo and AstraZeneca's Datopotamab Deruxtecan shows improved survival rates versus chemotherapy in advanced nonsquamous non-small cell lung cancer patients in the TROPION-Lung01 Phase 3 trial. While the survival results favored the drug, they did not reach statistical significance. The trial had previously met the dual primary endpoint of progression-free survival. These results support ongoing regulatory reviews globally, including in the U.S. and EU.
May 28, 2024 | 7:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca's Datopotamab Deruxtecan shows improved survival rates in advanced lung cancer patients in the TROPION-Lung01 Phase 3 trial. While the results did not reach statistical significance, they support ongoing regulatory reviews globally.
The positive survival data, even if not statistically significant, combined with the previously met primary endpoint of progression-free survival, supports the ongoing regulatory reviews. This could lead to future approvals and market potential, positively impacting AstraZeneca's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Daiichi Sankyo's Datopotamab Deruxtecan shows improved survival rates in advanced lung cancer patients in the TROPION-Lung01 Phase 3 trial. While the results did not reach statistical significance, they support ongoing regulatory reviews globally.
The positive survival data, even if not statistically significant, combined with the previously met primary endpoint of progression-free survival, supports the ongoing regulatory reviews. This could lead to future approvals and market potential, positively impacting Daiichi Sankyo's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100